SCHEMBL5242947

SCHEMBL5242947

Cc1c(OCC(N)=O)ccc([C@@H](C)N2CCN(C(=O)c3ccc(Cl)cc3)CC2)c1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.47
▸ HRH3 Q9Y5N1 4/20 0.43
▸ SLC6A4 P31645 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ KCNA5 P22460 2/20 0.42
▸ DRD3 P35462 3/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ DRD2 P14416 2/20 0.40
▸ LDHA P00338 1/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA7 P43166 1/20 0.40
▸ CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5281413 0.91 CHRNA7 (0.48) CHRNA7HRH3SLC6A4POLBKCNA5
SCHEMBL5905582 0.88 CHRNA7 (0.47) CHRNA7HRH3SLC6A4POLBKCNA5
SCHEMBL5905043 0.87 EPHX2 (0.47) HRH3SLC6A4POLBDRD3MAPT
SCHEMBL5905425 0.87 CHRNA7 (0.47) CHRNA7HRH3SLC6A4POLBKCNA5
SCHEMBL5904941 0.87 CHRNA7 (0.48) CHRNA7HRH3SLC6A4POLBKCNA5
SCHEMBL5904995 0.87 CHRNA7 (0.48) CHRNA7HRH3SLC6A4POLBKCNA5
SCHEMBL5242490 0.87 CHRNA7 (0.48) CHRNA7HRH3SLC6A4POLBKCNA5
SCHEMBL5243770 0.87 CHRNA7 (0.48) CHRNA7HRH3SLC6A4POLBKCNA5
SCHEMBL5905461 0.87 CHRNA7 (0.48) CHRNA7HRH3SLC6A4POLBKCNA5
SCHEMBL5242621 0.86 CHRNA7 (0.46) CHRNA7HRH3SLC6A4POLBKCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756107-A2 ARYL-SUBSTITUTED PIPERAZINE DERIVATIVES NEUROGEN CORPORATION (US) 2007-02-28 — — EP claimed
WO-2006009789-A2 ARYL-SUBSTITUTED PIPERAZINE DERIVATIVES NEUROGEN CORPORATION (US) 2006-01-26 — — WO claimed
US-20060009456-A1 Aryl-substituted piperazine derivatives NEUROGEN CORPORATION 2006-01-12 — — US claimed
US-20060009456-A1 Aryl-substituted piperazine derivatives NEUROGEN CORPORATION 2006-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009456-A1 Aryl-substituted piperazine derivatives MCHR1, MCHR2, PRLHR CHRNA7 403/4885HRH3 136/4885SLC6A4 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback